2024
P170 Ixekizumab significantly improved quality of life and joint pain in patients with psoriatic arthritis, nail disease and distal interphalangeal joint involvement from SPIRIT-H2H
Ritchlin C, Kavanaugh A, Kristensen L, Merola J, Strober B, Lisse J, Bolce R, Sapin C, Pustizzi J, McGonagle D. P170 Ixekizumab significantly improved quality of life and joint pain in patients with psoriatic arthritis, nail disease and distal interphalangeal joint involvement from SPIRIT-H2H. Rheumatology 2024, 63: keae163.209. DOI: 10.1093/rheumatology/keae163.209.Peer-Reviewed Original ResearchHealth Assessment Questionnaire-Disability IndexDermatology Life Quality IndexSF-36Quality of lifeJoint painMental and Physical Component Summary scoresQoL measuresConsulting feesUCB PharmaPhysical component summary scoreHealth care providersComponent summary scoresSF-36 MCSSF-36 PCSIXE-treated patientsClinically important improvementNail Psoriasis Severity IndexADA-treated patientsDistal interphalangeal jointDistal interphalangeal joint involvementDermatology Life Quality Index scoresStatistically significant improvementVisual analogue scaleCare providersJoint involvementP176 Ixekizumab significantly improves nail disease and adjacent joint tenderness and swelling in psoriatic arthritis
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. P176 Ixekizumab significantly improves nail disease and adjacent joint tenderness and swelling in psoriatic arthritis. Rheumatology 2024, 63: keae163.215. DOI: 10.1093/rheumatology/keae163.215.Peer-Reviewed Original ResearchPost-baseline assessmentTreatment effectsEli Lilly and CompanyPost hoc analysisSevere functional impairmentStudy of adultsNail PsOFunctional impairmentAdjacent joint diseaseSPIRIT-H2HGroup levelHoc analysisPsoriatic arthritisJoint tendernessNail diseaseIndividual digitsPatients treated with ixekizumabNon-respondersEli LillyUCB PharmaJoint involvementJoint swellingCorEvitas Psoriasis RegistryCount scoreTreated with adalimumab
2023
P169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, Lisse J, Pustizzi J, Sapin C, Bolce R, Ritchlin C. P169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis. Rheumatology 2023, 62 DOI: 10.1093/rheumatology/kead104.210.Peer-Reviewed Original ResearchNail Psoriasis Severity IndexProportion of patientsPsoriatic arthritisWeek 24Nail diseaseNail involvementDIP involvementSanofi GenzymeWeek 52Total scoreEli LillyExact testNail bedUCB PharmaDistal interphalangeal (DIP) joint diseaseDistal interphalangeal joint involvementDifferent biological therapiesInterphalangeal joint involvementNail matrix involvementPsoriatic nail diseasePost-baseline assessmentPsoriasis Severity IndexNHS Greater GlasgowFisher's exact testTotal maximum scoreE088 Safety of guselkumab in patients with psoriatic disease: an integrated analysis of 11 Phase 2 and 3 clinical studies in psoriasis and psoriatic arthritis
Strober B, Coates L, Yu J, Rowland K, Leibowitz E, Miller M, Kollmeier A, Li S, Wang Y, Chan D, Chakravarty S, Yang Y, Shawi M, Lebwohl M, Rahman P. E088 Safety of guselkumab in patients with psoriatic disease: an integrated analysis of 11 Phase 2 and 3 clinical studies in psoriasis and psoriatic arthritis. Rheumatology 2023, 62 DOI: 10.1093/rheumatology/kead104.337.Peer-Reviewed Original ResearchGuselkumab-treated patientsJanssen Scientific AffairsGrant/research supportPlacebo-controlled periodPlacebo-treated patientsAdverse eventsBristol-Myers SquibbBoehringer IngelheimOpportunistic infectionsIncidence rateMeiji Seika PharmaSafety dataLEO PharmaEli LillyUCB PharmaMajor adverse cardiovascular eventsSafety eventsScientific AffairsAdverse cardiovascular eventsOverall adverse eventsSerious adverse eventsSevere plaque psoriasisPhase 2/3 studyActive psoriatic arthritisPharmaceutical companies
2022
POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS
Fleischmann R, Thaçi D, Gooderham M, Strober B, Korman N, Banerjee S, Lehman T, Nowak M, Sreih A, Morita A, Mease P. POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS. Annals Of The Rheumatic Diseases 2022, 81: 835.2-836. DOI: 10.1136/annrheumdis-2022-eular.1862.Peer-Reviewed Original ResearchConcomitant conventional synthetic DMARDsPhase 2 trialGrant/research supportKyowa Hakko KirinBristol-Myers SquibbCommon Terminology CriteriaPhase 3 trialSanofi GenzymeWeeks of treatmentLaboratory parametersPsoriatic arthritisLEO PharmaBoehringer IngelheimSun Pharmaceutical IndustriesUCB PharmaSpeaker feesNippon KayakuPlacebo nPsA trialsPsoriasis RegistryTerminology CriteriaWk 1Eli LillyLarge phase 3 trialsMitsubishi Tanabe
2018
Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies
Blauvelt A, Strober B, Langley R, Burge D, Pisenti L, Yassine M, Kavanagh S, Arendt C, Rolleri R, Reich K. Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. SKIN The Journal Of Cutaneous Medicine 2018, 2: s16. DOI: 10.25251/skin.2.supp.16.Peer-Reviewed Original Research